These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 31579995)

  • 21. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity.
    Patton KK; Heckbert SR; Alonso A; Bahrami H; Lima JA; Burke G; Kronmal RA
    Heart; 2013 Dec; 99(24):1832-6. PubMed ID: 24131775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation.
    Matusik PT; Małecka B; Lelakowski J; Undas A
    Clin Res Cardiol; 2020 Apr; 109(4):426-434. PubMed ID: 31280356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incremental predictive value of pre-procedural N-terminal pro-B-type natriuretic peptide for short-term recurrence in atrial fibrillation ablation.
    Hwang HJ; Son JW; Nam BH; Joung B; Lee B; Kim JB; Lee MH; Jang Y; Chung N; Shim WH; Cho SY; Kim SS
    Clin Res Cardiol; 2009 Apr; 98(4):213-8. PubMed ID: 19229464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of N-terminal pro-B-type natriuretic peptide level in screening for atrial fibrillation in primary health care.
    Ghazal F; Theobald H; Rosenqvist M; Al-Khalili F
    PLoS One; 2019; 14(2):e0212974. PubMed ID: 30807614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of the Atrial Electromechanical Delay in Predicting Atrial Fibrillation in Myotonic Dystrophy Type 1 Patients.
    Russo V; Rago A; Ciardiello C; Russo MG; Calabrò P; Politano L; Nigro G
    J Cardiovasc Electrophysiol; 2016 Jan; 27(1):65-72. PubMed ID: 26331589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amino-terminal B-natriuretic peptide levels and postablation recurrence in hypertensive patients with paroxysmal atrial fibrillation.
    Giannopoulos G; Kossyvakis C; Angelidis C; Efremidis M; Panagopoulou V; Letsas K; Bouras G; Vassilikos VP; Goudevenos J; Tousoulis D; Lekakis J; Deftereos S
    Heart Rhythm; 2015 Jul; 12(7):1470-5. PubMed ID: 25847478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers predictive of atrial fibrillation in patients with cryptogenic stroke. Insights from the Nordic Atrial Fibrillation and Stroke (NOR-FIB) study.
    Tancin Lambert A; Ratajczak-Tretel B; Al-Ani R; Arntzen K; Bakkejord GK; Bekkeseth HMO; Bjerkeli V; Eldøen G; Gulsvik AK; Halvorsen B; Høie GA; Ihle-Hansen H; Ihle-Hansen H; Ingebrigtsen S; Johansen H; Kremer C; Krogseth SB; Kruuse C; Kurz M; Nakstad I; Novotny V; Naess H; Qazi R; Rezai MK; Rørholt DM; Steffensen LH; Sømark J; Tobro H; Truelsen TC; Wassvik L; AEgidius KL; Pesonen M; de Melis M; Atar D; Aamodt AH;
    Eur J Neurol; 2023 May; 30(5):1352-1363. PubMed ID: 36786305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B-type natriuretic peptide level after sinus rhythm restoration in patients with persistent atrial fibrillation - clinical significance.
    Wozakowska-Kapłon B; Bartkowiak R; Grabowska U; Janiszewska G
    Kardiol Pol; 2010 Jul; 68(7):781-6. PubMed ID: 20648436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke.
    Kneihsl M; Gattringer T; Bisping E; Scherr D; Raggam R; Mangge H; Enzinger C; Fandler-Höfler S; Eppinger S; Hermetter C; Bucnik B; Poltrum B; Niederkorn K; Fazekas F
    Stroke; 2019 Aug; 50(8):2223-2226. PubMed ID: 31216968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of Future Atrial Fibrillation Development in Patients with Hypertrophic Cardiomyopathy: A Prospective Follow-Up Study.
    Tuluce K; Yakar Tuluce S; Kahya Eren N; Kocabas U; Akyildiz Akcay F; Gunduz R; Akyildiz ZI; Ergene O
    Echocardiography; 2016 Mar; 33(3):379-85. PubMed ID: 26493159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study.
    Charitakis E; Walfridsson H; Alehagen U
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac involvement in myotonic dystrophy: The role of troponins and N-terminal pro B-type natriuretic peptide.
    Valaperta R; De Siena C; Cardani R; Lombardia F; Cenko E; Rampoldi B; Fossati B; Brigonzi E; Rigolini R; Gaia P; Meola G; Costa E; Bugiardini R
    Atherosclerosis; 2017 Dec; 267():110-115. PubMed ID: 29121498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of pathophysiological pathways for incident atrial fibrillation using a multiplex proteomic chip.
    Molvin J; Jujic A; Melander O; Pareek M; Råstam L; Lindblad U; Daka B; Leosdottir M; Nilsson P; Olsen M; Magnusson M
    Open Heart; 2020; 7(1):e001190. PubMed ID: 32201587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive Value of NT-proBNP for New-onset Atrial Fibrillation in the Acute Phase of Myocardial Infarction.
    Dong Z; Hou X; Guo C
    Altern Ther Health Med; 2024 Oct; 30(10):528-532. PubMed ID: 38401102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design.
    Engdahl J; Svennberg E; Friberg L; Al-Khalili F; Frykman V; Kemp Gudmundsdottir K; Fredriksson T; Rosenqvist M
    Europace; 2017 Feb; 19(2):297-302. PubMed ID: 28011798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.
    Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Ezekowitz MD; Hohnloser SH; Reilly PA; Vinereanu D; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2012 Apr; 125(13):1605-16. PubMed ID: 22374183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum N-terminal-pro-brain natriuretic peptide level and its clinical implications in patients with atrial fibrillation.
    Bai M; Yang J; Li Y
    Clin Cardiol; 2009 Dec; 32(12):E1-5. PubMed ID: 20014208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and echocardiographic characteristics of individuals aged 75/76 years old with screening-detected elevated NT-proBNP levels.
    Al-Khalili F; Kemp-Gudmundsdottir K; Svennberg E; Fredriksson T; Frykman V; Friberg L; Rosenqvist M; Engdahl J
    Open Heart; 2020; 7(1):e001200. PubMed ID: 32153793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diagnostic value of copeptin and cancer antigen 125 in acute heart failure patients with atrial fibrillation and their correlations with short-term cardiovascular events].
    Ding Y; Wang Q; Yang Y; Wang L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Nov; 30(11):1024-1028. PubMed ID: 30541639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.